FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4220930157> ?p ?o ?g. }

• W4220930157 endingPage "115200" @default.
• W4220930157 startingPage "115200" @default.
• W4220930157 abstract "Rheumatoid arthritis is one of the most common disabling chronic progressive autoimmune diseases affecting the adult world population. Boswellia serrata has been a known anti-inflammatory agent since ancient times. Therefore, research on Boswellia extract based on Acetyl Keto Boswellic Acid (AKBA) content evaluating its efficacy and safety is necessary. The study aimed to find a suitable Boswellia extract rich in AKBA to evaluate its bioavailability, anti-inflammatory, and anti-arthritic effect. In addition, the synergistic action of AKBA extract with methotrexate (MTX) was also assessed on an animal model.Oral bioavailability of AKBA and the anti-inflammatory activity of 10% AKBA (5, 10, 20, 40 mg/kg b.w) was assessed and compared with 2% AKBA (40 mg/kg) and diclofenac (10 mg/kg). The effect of 10% AKBA at 20 mg/kg and 40 mg/kg was evaluated in the FCA induced arthritis animal model alone and combined with methotrexate (MTX) at 2 mg/kg b.w. Subplantar injection of FCA produced edema within a few hours with progressive arthritis by the 9th day after injection. All the treatments were initiated from the 10th day until the 45th day. Oral administration of 10% AKBA was done daily and MTX by intraperitoneal route once a week from day 10 to day 45. Paw volume, erythrocyte sedimentation rate (ESR), serum glutamic oxaloacetic transaminase (SGOT), serum glutamic pyruvic transaminase (SGPT), alkaline phosphatase (ALP), total bilirubin, oxidative markers (superoxide dismutase (SOD) levels, malondialdehyde (MDA), total proteins and liver histopathology were examined.10% AKBA provided 8.48-fold, 24.22-fold, 47.36-fold, and 110.53-fold higher AUC (0-α) of AKBA at 5 mg/kg, 10 mg/kg, 20 mg/kg and 40 mg/kg, respectively compared to 2% AKBA at 40 mg/kg. Percentage paw edema inhibition of 10% AKBA at 20 mg/kg and 40 mg/kg were significantly higher than 2% regular AKBA (40 mg/kg) and diclofenac (10 mg/kg). 10% AKBA at a dose of 20 and 40 mg/kg significantly reduced ESR compared with FCA treated group. A combination of methotrexate with 10% AKBA showed the highest reduction in ESR. 10% AKBA at both dose levels significantly reduced hepatic marker enzymes and total bilirubin levels. Treatment with 10% AKBA showed a significant increase in total proteins, antioxidant enzymes and a decrease in malondialdehyde levels. Similarly, 10% AKBA protected the hepatocytes compared with the FCA and FCA + MTX treated group. 10% AKBA was capable of significantly minimizing FCA and FCA + MTX induced changes.Anti-inflammatory activity of AKBA due to inhibition of lipoxygenase (LOX) enzymes supports the use of AKBA in inflammatory disorders. Combination therapy of 10% AKBA with MTX is effective in inhibiting arthritis and circumventing hepatotoxicity produced by MTX in arthritic animals." @default.
• W4220930157 created "2022-04-03" @default.
• W4220930157 creator A5041142711 @default.
• W4220930157 creator A5051224941 @default.
• W4220930157 creator A5055503018 @default.
• W4220930157 creator A5060004499 @default.
• W4220930157 creator A5073449837 @default.
• W4220930157 date "2022-06-01" @default.
• W4220930157 modified "2023-10-09" @default.
• W4220930157 title "Bioavailability, anti-inflammatory and anti-arthritic effect of Acetyl Keto Boswellic acid and its combination with methotrexate in an arthritic animal model" @default.
• W4220930157 cites W1522182824 @default.
• W4220930157 cites W1540384225 @default.
• W4220930157 cites W1549470277 @default.
• W4220930157 cites W1750690213 @default.
• W4220930157 cites W1751584121 @default.
• W4220930157 cites W1775749144 @default.
• W4220930157 cites W1911137613 @default.
• W4220930157 cites W1967694992 @default.
• W4220930157 cites W1970620899 @default.
• W4220930157 cites W1981886300 @default.
• W4220930157 cites W1983310681 @default.
• W4220930157 cites W1984455266 @default.
• W4220930157 cites W1985363587 @default.
• W4220930157 cites W1991933724 @default.
• W4220930157 cites W1993764479 @default.
• W4220930157 cites W1993940604 @default.
• W4220930157 cites W1996868029 @default.
• W4220930157 cites W2016647963 @default.
• W4220930157 cites W2020703353 @default.
• W4220930157 cites W2021259437 @default.
• W4220930157 cites W2027105042 @default.
• W4220930157 cites W2035158278 @default.
• W4220930157 cites W2039905002 @default.
• W4220930157 cites W2044004638 @default.
• W4220930157 cites W2046740654 @default.
• W4220930157 cites W2055067214 @default.
• W4220930157 cites W2057316443 @default.
• W4220930157 cites W2066076204 @default.
• W4220930157 cites W2069733693 @default.
• W4220930157 cites W2087652191 @default.
• W4220930157 cites W2088841049 @default.
• W4220930157 cites W2091566696 @default.
• W4220930157 cites W2091708115 @default.
• W4220930157 cites W2101840353 @default.
• W4220930157 cites W2113680167 @default.
• W4220930157 cites W2117599348 @default.
• W4220930157 cites W2139124195 @default.
• W4220930157 cites W2140016144 @default.
• W4220930157 cites W2149148956 @default.
• W4220930157 cites W2256245458 @default.
• W4220930157 cites W2273452210 @default.
• W4220930157 cites W2581709974 @default.
• W4220930157 cites W2595795638 @default.
• W4220930157 cites W2938744541 @default.
• W4220930157 cites W2969548222 @default.
• W4220930157 doi "https://doi.org/10.1016/j.jep.2022.115200" @default.
• W4220930157 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35306043" @default.
• W4220930157 hasPublicationYear "2022" @default.
• W4220930157 type Work @default.
• W4220930157 citedByCount "2" @default.
• W4220930157 countsByYear W42209301572023 @default.
• W4220930157 crossrefType "journal-article" @default.
• W4220930157 hasAuthorship W4220930157A5041142711 @default.
• W4220930157 hasAuthorship W4220930157A5051224941 @default.
• W4220930157 hasAuthorship W4220930157A5055503018 @default.
• W4220930157 hasAuthorship W4220930157A5060004499 @default.
• W4220930157 hasAuthorship W4220930157A5073449837 @default.
• W4220930157 hasConcept C126322002 @default.
• W4220930157 hasConcept C142724271 @default.
• W4220930157 hasConcept C181199279 @default.
• W4220930157 hasConcept C181389837 @default.
• W4220930157 hasConcept C185592680 @default.
• W4220930157 hasConcept C204787440 @default.
• W4220930157 hasConcept C2775838275 @default.
• W4220930157 hasConcept C2776151105 @default.
• W4220930157 hasConcept C2777077863 @default.
• W4220930157 hasConcept C2777575956 @default.
• W4220930157 hasConcept C2778401633 @default.
• W4220930157 hasConcept C2780574456 @default.
• W4220930157 hasConcept C2781059491 @default.
• W4220930157 hasConcept C55493867 @default.
• W4220930157 hasConcept C556039675 @default.
• W4220930157 hasConcept C71924100 @default.
• W4220930157 hasConcept C98274493 @default.
• W4220930157 hasConceptScore W4220930157C126322002 @default.
• W4220930157 hasConceptScore W4220930157C142724271 @default.
• W4220930157 hasConceptScore W4220930157C181199279 @default.
• W4220930157 hasConceptScore W4220930157C181389837 @default.
• W4220930157 hasConceptScore W4220930157C185592680 @default.
• W4220930157 hasConceptScore W4220930157C204787440 @default.
• W4220930157 hasConceptScore W4220930157C2775838275 @default.
• W4220930157 hasConceptScore W4220930157C2776151105 @default.
• W4220930157 hasConceptScore W4220930157C2777077863 @default.
• W4220930157 hasConceptScore W4220930157C2777575956 @default.
• W4220930157 hasConceptScore W4220930157C2778401633 @default.
• W4220930157 hasConceptScore W4220930157C2780574456 @default.
• W4220930157 hasConceptScore W4220930157C2781059491 @default.
• W4220930157 hasConceptScore W4220930157C55493867 @default.

• next